Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:FTLF NASDAQ:MDWD NASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.88-1.2%$5.01$1.00▼$7.00$43.27M0.49,585 shs17,747 shsFTLFFitLife Brands$17.64-2.7%$15.51$9.83▼$19.19$170.26M0.6513,612 shs11,097 shsMDWDMediWound$17.84-6.4%$18.58$14.14▼$22.50$205.99M0.25149,122 shs208,497 shsVTYXVentyx Biosciences$2.30-3.4%$2.68$0.78▼$3.39$169.71M0.95418,492 shs462,313 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-1.21%-3.75%-5.06%+10.91%+272.52%FTLFFitLife Brands-2.70%-5.82%+8.75%+26.00%+5.63%MDWDMediWound-6.40%+9.52%-4.85%-12.63%+4.27%VTYXVentyx Biosciences-3.36%-8.73%-19.30%-10.16%+9.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.88-1.2%$5.01$1.00▼$7.00$43.27M0.49,585 shs17,747 shsFTLFFitLife Brands$17.64-2.7%$15.51$9.83▼$19.19$170.26M0.6513,612 shs11,097 shsMDWDMediWound$17.84-6.4%$18.58$14.14▼$22.50$205.99M0.25149,122 shs208,497 shsVTYXVentyx Biosciences$2.30-3.4%$2.68$0.78▼$3.39$169.71M0.95418,492 shs462,313 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-1.21%-3.75%-5.06%+10.91%+272.52%FTLFFitLife Brands-2.70%-5.82%+8.75%+26.00%+5.63%MDWDMediWound-6.40%+9.52%-4.85%-12.63%+4.27%VTYXVentyx Biosciences-3.36%-8.73%-19.30%-10.16%+9.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00145.90% UpsideFTLFFitLife Brands 2.67Moderate Buy$23.0030.39% UpsideMDWDMediWound 2.80Moderate Buy$32.2580.77% UpsideVTYXVentyx Biosciences 2.50Moderate Buy$7.50226.09% UpsideCurrent Analyst Ratings BreakdownLatest ATHE, VTYX, MDWD, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025FTLFFitLife BrandsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025FTLFFitLife BrandsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AFTLFFitLife Brands$63.05M2.63$0.99 per share17.90$3.93 per share4.49MDWDMediWound$20.22M9.54N/AN/A$2.89 per share6.17VTYXVentyx BiosciencesN/AN/AN/AN/A$3.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$7.87MN/A0.00∞N/AN/AN/AN/AN/AFTLFFitLife Brands$8.98M$0.8421.0016.04N/A12.63%21.70%13.45%N/AMDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)VTYXVentyx Biosciences-$135.12M-$1.68N/AN/AN/AN/A-48.89%-44.87%11/6/2025 (Estimated)Latest ATHE, VTYX, MDWD, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FTLFFitLife Brands$0.18$0.18N/A$0.18$16.17 million$16.13 million8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/7/2025Q2 2025VTYXVentyx Biosciences-$0.45-$0.38+$0.07-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A12.9812.98FTLFFitLife Brands0.151.710.81MDWDMediWoundN/A1.481.35VTYXVentyx BiosciencesN/A19.1219.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%FTLFFitLife Brands2.32%MDWDMediWound46.83%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%FTLFFitLife Brands61.40%MDWDMediWound9.20%VTYXVentyx Biosciences14.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableMDWDMediWound8010.81 million9.81 millionOptionableVTYXVentyx Biosciences3071.31 million60.98 millionOptionableATHE, VTYX, MDWD, and FTLF HeadlinesRecent News About These CompaniesIeq Capital LLC Takes Position in Ventyx Biosciences, Inc. $VTYXSeptember 9, 2025 | marketbeat.comNuveen LLC Makes New $194,000 Investment in Ventyx Biosciences, Inc. $VTYXSeptember 8, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 157,070 Shares of Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comRedmile Group LLC Raises Holdings in Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comH.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comVentyx Biosciences Reports Decreased Losses in 2025August 15, 2025 | msn.com3 Best Stocks to Buy Now, 8/11/2025, According to Top AnalystsAugust 11, 2025 | msn.comVentyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate ProgressAugust 9, 2025 | finance.yahoo.comVentyx (VTYX) Q2 Net Loss Drops 16%August 9, 2025 | theglobeandmail.comIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 10, 2025 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comVentyx Biosciences' Study of VTX3232 Met Safety, Tolerability ObjectivesJune 17, 2025 | marketwatch.comVentyx says Parkinson’s disease drug hit main goal in small mid-stage trialJune 17, 2025 | msn.comVentyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial ResultsJune 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Not Just NVDA: 3 Semiconductor Stocks Struggling This QuarterBy Dan Schmidt | September 12, 2025ATHE, VTYX, MDWD, and FTLF Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.88 -0.06 (-1.21%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$4.90 +0.03 (+0.51%) As of 09/12/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.FitLife Brands NASDAQ:FTLF$17.64 -0.49 (-2.70%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.65 +0.01 (+0.06%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.MediWound NASDAQ:MDWD$17.84 -1.22 (-6.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.86 +0.02 (+0.08%) As of 09/12/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Ventyx Biosciences NASDAQ:VTYX$2.30 -0.08 (-3.36%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.34 +0.04 (+1.74%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
